These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31945495)

  • 1. Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
    Delaunay T; Achard C; Boisgerault N; Grard M; Petithomme T; Chatelain C; Dutoit S; Blanquart C; Royer PJ; Minvielle S; Quetel L; Meiller C; Jean D; Fradin D; Bennouna J; Magnan A; Cellerin L; Tangy F; Grégoire M; Fonteneau JF
    J Thorac Oncol; 2020 May; 15(5):827-842. PubMed ID: 31945495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
    Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
    Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment.
    Chatelain C; Berland L; Grard M; Jouand N; Fresquet J; Nader J; Hirigoyen U; Petithomme T; Combredet C; Pons-Tostivint E; Fradin D; Treps L; Blanquart C; Boisgerault N; Tangy F; Fonteneau JF
    Oncoimmunology; 2024; 13(1):2377830. PubMed ID: 39005546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
    Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
    Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
    Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
    Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of Vaccine-Strain Measles Viruses for Cancer Therapy?
    Peikert T
    J Thorac Oncol; 2020 May; 15(5):689-691. PubMed ID: 32340675
    [No Abstract]   [Full Text] [Related]  

  • 7. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
    Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
    Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.
    Li H; Peng KW; Dingli D; Kratzke RA; Russell SJ
    Cancer Gene Ther; 2010 Aug; 17(8):550-8. PubMed ID: 20379224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.
    Yang H; Xu D; Gao Y; Schmid RA; Peng RW
    J Thorac Oncol; 2020 Jul; 15(7):e111-e113. PubMed ID: 32593447
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.
    Jean D; Delaunay T; Meiller C; Boisgerault N; Grard M; Caruso S; Blanquart C; Felley-Bosco E; Bennouna J; Tangy F; Grégoire M; Fonteneau JF
    J Thorac Oncol; 2020 Jul; 15(7):e113-e116. PubMed ID: 32593448
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
    Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
    Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
    Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
    J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Synergistic Effect of NF-κB Signaling Pathway Inhibitor and Oncolytic 
Measles Virus Vaccine Strain against Lung Cancer and Underlying Mechanisms].
    Xia M; Meng G; Dong J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):245-253. PubMed ID: 33775041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
    Kurokawa C; Iankov ID; Anderson SK; Aderca I; Leontovich AA; Maurer MJ; Oberg AL; Schroeder MA; Giannini C; Greiner SM; Becker MA; Thompson EA; Haluska P; Jentoft ME; Parney IF; Weroha SJ; Jen J; Sarkaria JN; Galanis E
    J Natl Cancer Inst; 2018 Oct; 110(10):1123-1132. PubMed ID: 29788332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
    Kelly KJ; Woo Y; Brader P; Yu Z; Riedl C; Lin SF; Chen N; Yu YA; Rusch VW; Szalay AA; Fong Y
    Hum Gene Ther; 2008 Aug; 19(8):774-82. PubMed ID: 18754710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
    Watanabe Y; Kojima T; Kagawa S; Uno F; Hashimoto Y; Kyo S; Mizuguchi H; Tanaka N; Kawamura H; Ichimaru D; Urata Y; Fujiwara T
    Oncogene; 2010 Feb; 29(8):1145-54. PubMed ID: 19935710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
    Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
    PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus.
    Aref S; Castleton AZ; Bailey K; Burt R; Dey A; Leongamornlert D; Mitchell RJ; Okasha D; Fielding AK
    Mol Ther; 2020 Apr; 28(4):1043-1055. PubMed ID: 32087150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
    Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.